At CancerWorld, we see cancer care as a meeting point of breakthrough science, human resilience, and the systems that connect them. The August 2025 issue brings that intersection into sharp relief, with a two-sided cover that pairs scientific ingenuity with the fight for equity.
On one cover, Dr. Jennifer Buell shares the extraordinary rise of MiNK Therapeutics and its off-the-shelf iNKT cell therapy that is quietly redrawing the map of immuno-oncology. On the other, Jayasree K. Iyer, CEO of the Access to Medicine Foundation, confronts the industry’s blind spot: the treatments exist, but for 80% of the world, they remain out of reach. Her story is a call to turn innovation into an equitable reality.
Between these two poles, breakthrough and access, this issue explores the many ways science, policy, culture, and compassion collide.
We see how an AI tool, FaceAge, can predict survival from a simple photo, challenging clinicians to rethink prognostic cues.
We meet Prof. Michel Goldman, the immunologist-turned-lymphoma-patient who never stopped teaching, even as his own cells turned against him.
We investigate why folk remedies still hold sway in Eastern Europe’s cancer communities, where mistrust and uneven care feed dangerous detours from evidence-based medicine.
We delve into Cancer Neuroscience, where Professors Frank Winkler and Michelle Monje’s discovery that neurons can ‘feed’ tumours not only opens an entirely new therapeutic frontier but has also earned them the prestigious Brain Prize.
We hear a survivor’s open letter to oncologists, Sandy Duarte’s reminder that medicine must meet meaning, and that sometimes a hug heals as much as a drug.
We examine the link between BRCA mutations and breast-implant–associated lymphoma, a warning for survivors and clinicians alike.
In a rare AI-authored reflection, Albertina considers the “art” of personalised hope, how algorithms can guide hands, but human connection gives purpose.
We honour Dr. Anne Merriman, whose vision for palliative care transformed lives across Africa and whose legacy now challenges a continent to carry the work forward.
Two covers, ten stories, one through-line: progress is not just about what we can do in the lab, but what we choose to make possible in the world.
Yeva Margaryan, Managing Editor, CancerWorld
